Información de la revista
Vol. 20. Núm. 3.
Páginas 123-127 (Marzo 2024)
Compartir
Descargar PDF
Más opciones de artículo
Vol. 20. Núm. 3.
Páginas 123-127 (Marzo 2024)
Original article
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
El uso de secukinumab tras la terapia anti-TNF es mayor de lo esperado por el riesgo de desarrollar enfermedad inflamatoria intestinal?
Fatih Albayraka,
, Mustafa Gürb, Ahmet Karataşb, Süleyman Serdar Kocab, Bünyamin Kısacıkc
Autor para correspondencia
a Department of Internal Medicine, Division of Rheumatology, Dr. Ersin Arslan Training and Research Hospital, Şehitkamil, Gaziantep, Turkey
b Department of Internal Medicine, Division of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey
c Department of Rheumatology, Gaziantep Sanko Hospital, Şehitkamil, Gaziantep, Turkey
Estadísticas
Siga este enlace para acceder al texto completo del artículo
Original article
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
El uso de secukinumab tras la terapia anti-TNF es mayor de lo esperado por el riesgo de desarrollar enfermedad inflamatoria intestinal?
Fatih Albayraka,
, Mustafa Gürb, Ahmet Karataşb, Süleyman Serdar Kocab, Bünyamin Kısacıkc
Autor para correspondencia
a Department of Internal Medicine, Division of Rheumatology, Dr. Ersin Arslan Training and Research Hospital, Şehitkamil, Gaziantep, Turkey
b Department of Internal Medicine, Division of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey
c Department of Rheumatology, Gaziantep Sanko Hospital, Şehitkamil, Gaziantep, Turkey
Siga este enlace para acceder al texto completo del artículo